A5010486276- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- HIV Research and Treatment
- HIV/AIDS Impact and Responses
- HIV/AIDS drug development and treatment
Marien Ngouabi University
2021-2025
Centre Hospitalier et Universitaire de Brazzaville
2024
Laboratoire de Microbiologie Fondamentale et Pathogénicité
2021
Institut Polytechnique de Bordeaux
2021
Université de Bordeaux
2021
Centre National de la Recherche Scientifique
2021
Introduction Virological failure is one of the major causes treatment failure, and better management HIV infection requires understanding controlling factors that contribute to this phenomenon. The main objective was characterize patients active file Brazzaville Outpatient Treatment Center in virological order identify predictive lead failure. Methods This a cross-sectional study conducted between June December 2020. Patients enrolled were HIV-1 infected from receiving potent combination...
Introduction Virological failure is one of the major causes treatment failure, and better management HIV infection requires understanding controlling factors that contribute to this phenomenon. The main objective was characterize patients active file Brazzaville Outpatient Treatment Center in virological order identify predictive lead failure. Methods This a cross-sectional study conducted between June December 2020. Patients enrolled were HIV-1 infected from receiving potent combination...
Virological failure is one of the main causes failing to treat, and better management HIV infection requires understanding controlling factors that contribute this phenomenon. The objective was characterize patients active file Brazzaville Outpatient Treatment Center in virological identify predictive leading failure.
HIV infects around one hundred thousand patients in the Republic of Congo. Approximately 25% them receive an antiretroviral treatment; current first-line regimens include two NRTIs and NNRTI, reverse transcriptase inhibitors. Recently, protease inhibitors (PIs) were also introduced as second-line therapy upon clinical signs treatment failure. Due to limited number molecular characterizations amount drug resistance data available Congo, this study aims evaluate prevalence circulating mutations within